Objectives: This paper describes characteristics of opioid use episodes for noncancer pain and defines thresholds for de facto long-term opioid therapy.
M
illions of Americans now receive opioid therapy for chronic noncancer pain, 1 but little is known about the duration or other characteristics of opioid use episodes for chronic noncancer pain. Societal and personal risks of increased prescribing of opioid analgesics (eg, abuse, diversion, accidental injury, and other adverse health effects) need to be weighed against potential benefits.
2-7 This is particularly true for the minority of patients who elect to continue use of opioids over long periods of time. Unfortunately, neither risks nor benefits of long-term opioid therapy are well understood. 8 Randomized trials have been too small and too short, typically lasting no more than 12 weeks. [9] [10] [11] [12] No large observational cohort studies have assessed the safety of long-term opioid use under community practice or ''real-world'' conditions. In community practice, it is unclear to what extent long-term opioid therapy is preplanned and monitored, 8 as recommended by expert guidelines. 13 De facto long-term opioid therapy is defined by treatment patterns that occur in real-world practice, as opposed to treatment patterns recommended by expert guidelines. De facto long-term opioid therapy is defined by extended use of opioids for chronic pain whether explicitly preplanned or not. Long-term opioid therapy may evolve through patient self-selection in the absence of evaluation of patient suitability for long-term opioid therapy, an agreed upon treatment plan, or monitoring of medication use and patients outcomes by the prescribing physician(s).
With support from the National Institute of Drug Abuse, CONSORT (CONsortium to Study Opioid Risks and Trends) was developed to improve understanding of trends in, and risks of, long-term opioid therapy for chronic noncancer pain. CONSORT data are intended to provide new information regarding trends in how opioid medications are used under community practice conditions and to evaluate associated risks. The objectives of this paper are to provide an overview of CONSORT methods used to characterize and classify opioid use episodes, to define de facto long-term opioid therapy, and to describe the characteristics of long-term opioid use episodes in 2 large health plan populations over a 10-year study period.
MATERIALS AND METHODS

Setting and Participants
CONSORT was initiated to study the use of opioids for noncancer pain among adults of age 18+ in Group Health Cooperative (located in Washington State) and Kaiser Permanente of Northern California over a 10-year period (from the years 1997 to 2006). The 2 health plans serve about 4 million persons-over 1% of the US population. CONSORT research plans were reviewed and approved by the Institutional Review Boards of both health plans.
The demographics of Group Health and Kaiser Permanente are similar to those of their respective regions. 14, 15 There are fewer African-Americans in Western Washington and Northern California than in the US population as a whole, but more Asians and Pacific Islanders. Kaiser Permanente's membership includes 6% African-Americans, 12% Hispanics, and 17% Asian/Pacific Islanders, whereas Group Health includes 3% African-Americans, 2% Hispanics, and 4% Asian/ Pacific Islanders. The populations of both health plans are similar in terms of educational attainment and household income to their regional populations. Both health plans serve older populations enrolled in Medicare and lower income persons insured by Medicaid and State health insurance programs for low income populations.
Data Sources Automated Pharmacy and Medical Encounter Data
Both health plans maintain automated pharmacy and medical encounter data for all covered services, including services provided directly by the health plans and services rendered by other providers who bill the health plans. The pharmacy files contain 1 record/drug dispensed, including generic drug name, strength, directions for use, date dispensed, quantity dispensed, days supply, prescriber identification number, and National Drug Code. Kaiser Permanente and Group Health pharmacies are conveniently located in relation to clinics. Surveys at both health plans have consistently found that more than 90% of enrollees obtain almost all of their prescription medications through health plan pharmacies. 14, 15 Defining Episodes of Opioid Use CONSORT data on opioid use were developed using an episode approach. The beginning of an episode of opioid use was defined by a prescription for an orally or transdermally administered opioid with no prior prescription filled in the prior 6 months. The start date of an episode is the date the first opioid in the episode was dispensed. The last fill of an episode is defined as the last opioid dispensed with no subsequent opioid dispensings in the following 6 months. The end date of the episode is the date the medication should have run out after this last dispensing on the basis of the days supply field. More than 3 million new episodes of opioid use were identified from January 1, 1997 through December 31, 2005 at the 2 health plans, of which almost 150,000 were long-term. Opioid use was tracked until the end of 2006. All cancer patients were eliminated from CONSORT analyses by excluding persons who had received a diagnosis of cancer in the year the episode began or before that year. Cancer status was determined from the Cancer Surveillance and End Results Registries available at both health plans. This method excludes patients with a history of cancer who may have been using opioids for noncancer pain and patients using opioids for cancer pain.
Indication
Indication for prescription was not available on pharmacy records. At Group Health in the years 2001 to 2003, we determined indication through ICD-9 codes recorded on visit encounters to the prescribing physician that occurred within 90 days of the initial prescription (N = 151, 314 episodes of opioid use). It was possible to identify a preceding encounter within 90 days of the initial opioid prescription for 74.4% of the episodes. The most common diagnostic groups observed on the linked encounters were extremity pain (13.4%); back pain (13.3%); fractures, contusions, and injury (7.1%); abdominal pain/hernia (5.1%); osteoarthritis (3.8%); neck pain (3.6%); headache (2.6%); kidney stones/gall stones (1.9%); and menstrual/reproductive pain (1.0%).
Classification of Opioids
Opioids were classified into 3 major groups: longacting, Schedule II opioids; short-acting, Schedule II opioids; and short-acting, non-Schedule II opioids. The types of opioid medications within each group are listed in Table 1 , along with conversion factors for estimating morphine equivalent dosages from the milligrams of each type of opioid dispensed. The conversion factors were based on information from multiple sources. [16] [17] [18] [19] [20] After reviewing published conversion factors, consensus was reached among 2 physicians with clinical experience in pain management (M.S. and J.M.) and a pharmacist pharmacoepidemiologist (D.B.).
Total Morphine Equivalents
Total morphine equivalents for a single prescription was calculated by multiplying the quantity of each prescription by the strength of the prescription (milligrams of opioid/unit dispensed). The quantity Â strength product was then multiplied by the conversion factor for morphine equivalents (Table 1) to estimate the morphine equivalents for the prescription. Total morphine equivalents in an episode was calculated by adding the morphine equivalents for each prescription dispensed during the episode.
run-out date of the last prescription dispensed plus one. Total days supply is the sum of days supply for each opioid dispensed during an episode. Days supply may not represent the intended days supply of a particular prescription as it is usually calculated by pharmacists using the maximum dose and frequency permitted within the range specified by the prescribing provider. Therefore, total days supply tends to underestimate the actual days supply dispensed.
Average Daily Dose and Average Prescribed Dose
Average daily dose is the total morphine equivalents for an episode divided by episode duration in days. Average prescribed dose is the total morphine equivalents for an episode divided by total days supply for the episode, that is, the estimated average daily dose prescribed as opposed to the average daily dose consumed.
Type of Episode
On the basis of exploratory analyses to develop criteria for classifying episodes, each episode of opioid use was classified as acute, episodic, long-term/lower dose, or long-term/higher dose. Episodes lasting < 90 days were classified as acute. Episodes lasting 90 days or longer were classified as episodic if the total days supply was <120 and the total number of prescriptions filled was fewer than 10. Long-term opioid use episodes were defined by episode duration of 90+ days and 10+ opioid prescriptions or 120+ days supply of opioids dispensed. The thresholds of 120+ days supply and 10+ prescriptions dispensed was based on life table analyses that showed that the probability of another 10 days supply and an additional prescription being dispensed is high at those thresholds. These criteria provide an operational definition for de facto long-term opioid therapy. Long-term episodes were considered higher dose if the average daily dose was 20-mg morphine equivalents or greater, whereas episodes with <20-mg morphine equivalents were classified as lower dose. The empirical bases for these classification criteria are discussed further in the Results section.
Most Frequently Prescribed Opioid
The opioid with the largest total days supply in an episode was identified as the most frequently prescribed opioid in that episode. In case of ties, the opioid with the larger average prescribed dose was identified.
Data Quality Issues
We treated as an outlier any value for days supply or quantity dispensed that was greater than 2 times the 99th percentile value for a particular type of opioid. Outliers were then handled after procedures for other forms of missing data. If either quantity or days supply was missing for a particular prescription, then morphine equivalents were not calculated for that prescription. The estimate of total morphine equivalents was inflated by wTransmucosal fentanyl conversion to morphine equivalents assumes 50% bioavailability of transmucosal fentanyl and 100-mg transmucosal fentanyl is equivalent to 12.5 to 15 mg of oral morphine.
zTransdermal fentanyl conversion to morphine equivalents is based on the assumption that 1 patch delivers the dispensed micrograms/hour over a 24-hour day and remains in place for 3 days.
CONSORT indicates CONsortium to Study Opioid Risks and Trends. the total number of prescriptions in the episode (including those with missing data) divided by the number of prescriptions with valid data (ie, not counting the ones with missing/outlier data). This approach conservatively estimates total morphine equivalents for prescriptions with missing/outlier data as being equal to the average prescription in the episode. If more than one-tenth of the prescriptions in an episode had missing/outlier data, then the entire episode was set to missing. At both Group Health and Kaiser Permanente, total morphine equivalents was set to missing for <1% of all episodes.
Analyses
We present data on the most frequently prescribed type of opioid by the 4 episode types. We also present a profile of each type of episode (mean values of episode duration, total days supply, average daily dose, and average prescribed dose). The percentage of total days supply and the percentage of total morphine equivalents dispensed over the 10-year study period accounted for by each type of episode were also determined.
Evaluation of Episode Classification Criteria
Initially using Group Health data, we assessed the criteria for classifying de facto long-term opioid therapy episodes by their association with future level of opioid use. Using the data from the years 1997 to 1998, we identified and classified new opioid use episodes starting in the year 1997 for adult enrollees who remained enrolled from the year 1997 through year-end 2000. We then determined level of opioid use in the years 1999 to 2000. Persons with multiple episodes in the year 1997 or in the year 1999 were assigned to the highest level episode. We report the percentage of persons who met criteria for long-term opioid therapy in the years 1999 to 2000 among persons with higher dose and lower dose long-term opioid use episodes in the years 1997 to 1998. We then replicated these analyses using Kaiser Permanente data.
RESULTS
Evaluation of Episode Classification Criteria
Among persons initiating a new episode of longterm opioid therapy in the years 1997 to 1998 at Group Health Cooperative, 56.1% of those meeting criteria for higher dose therapy continued to meet criteria for longterm opioid therapy in the years 1999 to 2000. Among persons receiving long-term opioid therapy at lower dosage levels in the years 1997 to 1998, 46.3% continued to meet criteria for long-term opioid therapy in the years 1999 to 2000. The corresponding percentages at Kaiser Permanente Northern California were 68.4% and 68.3%, respectively. Among persons meeting criteria for longterm opioid therapy in the years 1997 to 1998, the percentage continuing either episodic or long-term use in the years 1999 to 2000 was 62.2% at Group Health and 74.1% at Kaiser Permanente Northern California. In contrast, among persons with episodic use of opioids in the years 1997 to 1999, the percentage meeting criteria for long-term opioid therapy in the years 1999 to 2000 was 6.5% at Group Health Cooperative and 7.4% at Kaiser Permanente Northern California. Thus, persons who surpassed the proposed thresholds for long-term opioid therapy were highly likely to continue frequent use of opioids in future years.
Opioids Prescribed
As shown in Table 2 , for all types of episodes starting in the years 1997 to 2005, the most frequently prescribed opioids were short-acting, non-Schedule II opioids. Short-acting, non-Schedule II opioids were also the most frequently prescribed opioids for long-term episodes. Hydrocodone with aspirin/acetaminophen was the most commonly prescribed opioid overall. It was also the most frequently prescribed opioid for longterm episodes, followed by codeine with aspirin/acetaminophen and propoxyphene.
A notable difference in prescribing patterns was observed between the 2 health plans. At Group Health, short-acting, non-Schedule II opioids were the most frequently prescribed for 74% of all episodes and for 65% of long-term episodes. At Kaiser Permanente, shortacting, non-Schedule II opioids were the most frequently prescribed medication for 98% of all episodes and for 91% of long-term episodes At Group Health, shortacting, Schedule II opioids were the most frequently prescribed drug for about one-fifth of all episodes and an equal proportion of long-term episodes. Oxycodone was the most commonly prescribed short-acting, Schedule II opioid. In contrast, at Kaiser Permanente, short-acting, Schedule II opioids were the most frequently prescribed medication for only 1.7% of all episodes and for 3.4% of the long-term episodes. Long-acting opioids were the most frequently prescribed medication for 1.5% of all episodes at Group Health and 0.4% of all episodes at Kaiser Permanente. Among long-term episodes, long-acting opioids were the most frequently prescribed medication for 12.4% of episodes at Group Health and 5.7% at Kaiser Permanente. At both health plans, the most commonly prescribed long-acting opioid for long-term episodes was sustained release morphine.
Profiles of Opioid Use by Episode Type
The profiles of opioid use in Table 3 show mean differences in opioid use patterns across the 4 types of episodes. Despite differences in prescribing of Schedule II short-acting and long-acting opioids between Group Health and Kaiser Permanente, the episode profiles were similar for the 2 health plans. By definition, acute episodes were typically brief (12 to 14 d on average), with a limited days supply of opioids dispensed (7 to 9 d on average). The average prescribed dose for acute episodes was somewhat greater at Kaiser Permanente (55 mg) than at Group Health (32 mg). Acute episodes represented 80% to 82% of the opioid use episodes initiated from the years 1997 to 2005, but these episodes accounted for only 18% to 19% of the total days supply dispensed and 12% to 16% of the total morphine equivalents dispensed over the 10-year study period.
Episodic use of opioids lasted, on average, about half a year, with a mean of 28 to 29 total days supply dispensed over the course of the episode. Although the average prescribed dose was similar to that of acute episodes, the average daily dose was substantially lower (5 to 6 mg), likely reflecting intermittent use. Episodic use accounted for 13% to 14% of all opioid use episodes from the years 1997 to 2005 and a somewhat smaller percentage of the total days supply of opioids and of total morphine equivalents dispensed over the 10-year study period.
Persons with long-term/lower-dose episodes continued to use opioids for about 850 days on average, but the mean total days supply during these episodes was less than half the number of days in the episodes. From available data, it is difficult to determine the extent to which long-term/lower dose episodes comprised low-dose daily use versus intermittent use. The low average daily The remaining opioid use episodes (<1.5% of all episodes) were long-term/higher dose episodes. These episodes continued for an average of about 1000 days and patients received an average of about 850 total days supply during these episodes, likely reflecting daily or near daily use. The average prescribed dose for these episodes was about 60 to 70-mg morphine equivalents, whereas the average daily dose was about 50 to 60-mg morphine equivalents. Although long-term/higher dose episodes accounted for about 1.5% of all episodes initiated in the years 1997 to 2005, these episodes accounted for 54% to 63% of the total morphine equivalents dispensed over the 10-year study period.
DISCUSSION
We developed a simple, empirically based classification of opioid use episodes, dividing them into acute, episodic, and long-term episodes, with the long-term episodes subdivided into lower and higher dose episodes. De facto long-term opioid therapy was operationally defined by episodes lasting at least 90 days with 10+ prescriptions or 120+ days supply of opioids dispensed. Acute episodes comprised about 80% of all opioid use episodes, but long-term/higher dose episodes (comprising <1.5% of all episodes) accounted for well over half of the total morphine equivalents dispensed over the 10-year study period. Long-term lower dose opioid use was more common than long-term daily or near daily use at higher dosage levels. Long-term/lower dose episodes may include both regular opioid use at low dosage levels and intermittent opioid use. Short-acting, non-Schedule II opioids were, by far, the most commonly prescribed medications for all types of episodes.
The profiles of acute, episodic, long-term/lower dose, and long-term/higher dose episodes were generally similar across the 2 health plans. A limitation of this study is that both the participating health plans were integrated health care delivery systems with prepaid, capitated insurance plans (ie, services were not provided on a fee-for-service basis). Prescribing patterns may differ from those of fee-for-service physicians and pharmacies that are not part of the same delivery system. However, a parallel study of opioid prescribing patterns in a large, commercially insured population has also found that non-Schedule II opioids were the most commonly prescribed, and that long-acting opioids were much less commonly prescribed among patients with frequent use of opioid medications. 21 The participating plans in this study have medical cultures and pharmacy policies that actively influence physician prescribing. Health plan pharmacists review physician prescribing in both settings. Both health plans have formularies and evidence review procedures for determining which medications are placed on the formulary. Access of pharmaceutical sales representatives to physicians is more restricted in both plans than in fee-for-service settings. These similarities may tend to reduce variability in prescribing patterns. Even so, notable differences in prescribing of Schedule II opioids were observed between Group Health and Kaiser Permanente of Northern California. Until California State law changed at the end of the year 2004, California required triplicate prescribing forms for Schedule II opioids. Washington State required triplicate prescribing forms only in conjunction with a disciplinary program. Triplicate form requirements have been shown to substantially reduce the prescribing of Schedule II opioids. 22 Other differences between the health plans and the patient and provider populations may have also played a role in the differences in prescribing of Schedule II opioids.
The American Academy of Pain Medicine and American Pain Society guidelines for long-term opioid therapy advocate therapy being initiated after thorough evaluation of the patient, development of a treatment plan, followed by periodic review of efficacy and progress toward agreed upon treatment goals. 13 It is unknown to what extent long-term opioid therapy in the health plans participating in this study, or in community practice generally, is consistent with these guidelines. The data presented here do not provide a basis for determining whether long-term opioid therapy was or was not planned in advance and guided by a documented and monitored treatment plan. It is likely that long-term opioid therapy often evolves through patient self-selection with physicians approving requested refills in the absence of an agreed upon treatment plan, but further research is needed to determine the extent to which long-term opioid therapy is planned versus unplanned. As the data presented in this paper were based largely on automated pharmacy data, no information on pain severity or functional status were available to characterize patient outcomes.
Several other features of the observed patterns of long-term opioid use merit further research. Patients receiving long-term opioid therapy most often used combination medications with acetaminophen or aspirin. The extent to which patients using compound medications are also receiving acetaminophen or aspirin from other sources deserves further study to assess potential health risks. 23 Propoxyphene was also commonly used in long-term opioid therapy, despite some evidence that it is no more effective than nonsteroidal anti-inflammatory drugs 24 and that, like other opioid medications, there are health risks when used with alcohol. 25 The relative effectiveness and safety of long-acting versus short-acting opioids is also an important issue for further research, as short-acting opioids were, by far, the most frequently prescribed in long-term opioid therapy.
Expert guidelines do not endorse long-term opioid therapy that occurs via patient self-selection rather than on the basis of a prospective treatment plan agreed upon by patient and physician with subsequent monitoring of progress. 13 By setting a clear boundary between acute and episodic use on the one hand and long-term use on the other, it may be possible for physicians and health plans to establish a checkpoint for making an explicit decision whether to sustain opioid treatment long-term, providing an opportunity to ensure that a treatment plan and provisions for monitoring medication use and patient outcomes have been developed with the patient. At both health plans, setting a threshold for long-term opioid therapy at an episode duration of >90 days with 10+ prescriptions or 120+ days supply dispensed would affect <6% of the episodes of opioid therapy for noncancer pain, but these episodes would account for the large majority of morphine equivalents dispensed on a population basis.
Summary
Episodes of long-term opioid therapy accounted for a small percentage of the opioid use episodes for noncancer pain in the study populations, but these episodes accounted for the large majority of morphine equivalents dispensed. De facto long-term opioid therapy was characterized by considerable variability in medications dispensed, dosage levels, and frequency of opioid use. The thresholds for long-term opioid therapy provide a possible checkpoint at which physicians could make an explicit decision about whether to sustain opioid therapy over the long-term, and for health plans to ensure that a documented treatment plan for long-term opioid therapy was developed and monitored by the prescribing physician.
